Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The SCD1 inhibitor aramchol interacts with regorafenib and metformin to kill tumor cells.

Oncotarget·2026
Same author

Day case and inpatient elective thyroid lobectomy across England: observational study of variation in practice and safety.

The British journal of surgery·2026
Same author

The SCD1 inhibitor aramchol interacts with regorafenib to kill GI tumor cells <i>in vitro</i> and <i>in vivo</i>.

Oncotarget·2025
Same author

GZ17-6.02 interacts with carboplatin and etoposide to kill neuroblastoma cells.

Anti-cancer drugs·2025
Same author

Multi-Objective Design and Optimization of Hardware-Friendly Grid-Based Sparse MIMO Arrays.

Sensors (Basel, Switzerland)·2024
Same author

Retraction Notice to: Inhibition of Multiple Protective Signaling Pathways and Ad.5/3 Delivery Enhances mda-7/IL-24 Therapy of Malignant Glioma.

Molecular therapy : the journal of the American Society of Gene Therapy·2024

Related Experiment Video

Updated: May 8, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Multi-kinase modulation for colon cancer therapy.

Paul Dent1

  • 1Department of Neurosurgery; Massey Cancer Center; Virginia Commonwealth University; Richmond, VA USA.

Cancer Biology & Therapy
|September 13, 2013
PubMed
Summary

Targeting multiple kinases simultaneously is crucial for effective cancer treatment, especially in aggressive colorectal cancer. This approach overcomes tumor resistance by inhibiting compensatory survival pathways, offering new therapeutic strategies.

Keywords:
BAY43-9006RAF inhibitorcetuximabcolorectal cancer therapycombined therapysorafenibsorafenib and cetuximab

More Related Videos

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer
06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

Related Experiment Videos

Last Updated: May 8, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer
06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Kinase inhibition is a key cancer therapy, but often requires targeting multiple complementary kinases simultaneously.
  • Tumor cells develop resistance through compensatory survival signaling mechanisms, necessitating combination therapies.
  • Genetic mutations, such as in K-RAS and B-RAF, dictate specific therapeutic vulnerabilities and resistance patterns in cancers like colorectal cancer.

Purpose of the Study:

  • To investigate the rational combination of signaling inhibitors for colon cancer patients with mutant B-RAF V600E.
  • To address the therapeutic challenges posed by aggressive colorectal cancer driven by specific oncogenic mutations.
  • To explore strategies for overcoming resistance mediated by compensatory survival signaling pathways.

Main Methods:

  • Clinical studies examining the efficacy of combined signaling inhibitors.
  • Analysis of tumor cell signaling pathways, including B-RAF V600E and downstream MEK1/2-ERK1/2.
  • Evaluation of compensatory activation of growth factor receptors following kinase inhibition.

Main Results:

  • Demonstrated a rational combination therapy approach for a specific colon cancer subtype.
  • Highlighted the role of mutant B-RAF V600E in driving aggressive tumor signaling.
  • Showcased the potential to overcome resistance mechanisms in colorectal cancer.

Conclusions:

  • Combined kinase inhibition strategies are essential for effectively treating cancers with complex mutational landscapes.
  • Targeting specific oncogenic drivers like B-RAF V600E in combination with other pathway inhibitors offers a promising therapeutic avenue for aggressive colorectal cancer.
  • Understanding and targeting compensatory survival signaling is critical for improving treatment outcomes in oncology.